Skip to main content

Table 4 Worst pain experienced after electroporation (Study 1) as measured by the McGill Pain Questionnaire (0-5) a

From: Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

 

V930 DNA-EP

V930 DNA-EP

Total

 

0.25 mg

2.5 mg

 
 

n (%)

n (%)

n (%)

Total number of patients

6

22

28

Worst pain experienced by patient:

   

entire study b

1 (17)

3 (14)

4 (14)

 0

2 (33)

4 (18)

6 (21)

 1

2 (33)

6 (27

8 (29)

 2

1 (17)

5 (23)

6 (21)

 3

0

2 (9)

2 (7)

 4

0

2 (9)

2 (7)

 5

   

Worst pain experienced by patient: day 1 b

   

 0

1 (17)

6 (27)

7 (25)

 1

3 (50)

5 (23)

8 (29)

 2

2 (33)

5 (23)

7 (25)

 3

0

4 (18)

4 (14)

 4

0

1 (5)

1 (4)

 5

0

1 (5)

1 (4)

Worst pain experienced by patient: day 15 b

   

 0

3 (50)

4 (18)

7 (25)

 1

3 (50)

6 (27)

9 (32)

 2

0

6 (27)

6 (21)

 3

0

3 (14)

3 (11)

 4

0

2 (9)

2 (7)

 5

0

1 (5)

1 (4)

Worst pain experienced by patient: day 29 b

   

 0

3 (50)

5 (23)

8 (29)

 1

1 (17)

5 (23)

6 (21)

 2

1 (17)

7 (32)

8 (29)

 3

1 (17)

2 (9)

3 (11)

 4

0

1 (5)

1 (4)

 5

0

2 (9)

2 (7)

Worst pain experienced by patient: day 43 b

   

 0

2 (33)

4 (18)

6 (21)

 1

2 (33)

8 (36)

10 (36)

 2

2 (33)

5 (23)

7 (25)

 3

0

2 (9)

2 (7)

 4

0

1 (5)

1 (4)

 5

0

2 (9)

2 (7)

Worst pain experienced by patient: day 57 b

   

 0

2 (33)

5 (23)

7 (25)

 1

2 (33)

8 (36)

10 (36)

 2

1 (17)

2 (9)

3 (11)

 3

1 (17)

3 (14)

4 (14)

 4

0

1 (5)

1 (4)

 5

0

2 (9)

2 (7)

  1. aThe McGill Pain Questionnaire measured pain on a 6-point scale: 0 = no pain, 1 = mild, 2 = discomforting, 3 = distressing, 4 = horrible, and 5 = excruciating.
  2. bAs ranked by the patient.